Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.
INDV - Indivior Pharmaceuticals Inc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$48.00
DETAILS
HIGH:
$53.00
LOW:
$43.00
MEDIAN:
$48.00
CONSENSUS:
$48.00
UPSIDE:
32.67%
Stock News
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propos
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this con.
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) PR Newsw
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV)
NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Indivior Pharmaceuticals, Inc. (NASDAQ: INDV ) related to its merger with Supernus Pharmaceuticals, Inc. Upon closing of the proposed transaction, Indivior shareholders will own approximately 56.5% of the combined company.
Supernus Pharmaceuticals (SUPN) Announces Transformative Merger with Indivior (INDV)
Supernus Pharmaceuticals (SUPN) has seen its stock rise following the announcement of an all-stock merger with Indivior (INDV). This strategic move comes alongs
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals Inc. (NASDAQ:INDV) on Monday agreed to unite through a tax-free all-stock merger of equals, forming a central nervous system (CNS) biopharmaceutical company.
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing of the Proposed Transaction, Indivior shareholders will own approximately 56.5% of the combined company.Halper Sadeh encourages Indivior shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersa.
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates
Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.51 per share a year ago.
Supernus, Indivior merge to strengthen neuroscience drug portfolio
Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that would create a company with about $2.2 billion in annual revenue and a portfolio of medicines for neurological, psychiatric and addiction-related conditions.
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
• Q2'26 Total Net Revenue of $ 343 Million, Up 14% YoY • Record Quarterly Total SUBLOCADE® Net Revenue of $ 253 Million in Q2'26, Up 21% YoY • Record Quarterly GAAP Net Income of $122 Million and Record Non-GAAP Net Income of $142 Million in Q2'26 • Record Quarterly Adjusted EBITDA of $ 186 Million in Q2'26, Up 111% YoY • Repurchased Approximately 4.7 Million Shares in Q2'26 for $175 Million RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the second quarter ended June 30, 2026, and raised its full-year 2026 financial guidance.
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
RICHMOND, Va., July 23, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT.
Billionaire Investor Howard Marks' Top 5 Holdings: A Buy at These Prices?
Howard Marks hunts dislocation. His latest Oaktree 13F reveals five common-stock equity positions that look nothing like a bull-market portfolio: a leveraged turbo maker, the largest US gas producer bleeding YTD, a gold miner that just gave back a fifth of its price in three months, a tanker riding a geopolitical spike, and a specialty pharma with negative book value.
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable
Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?
Indivior, a leader in opioid dependence therapies, reported a notable insider sale following a year of exceptional share price gains.
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026
Long-acting injectable adoption remains low, but Indivior's market position, payer access and consumer campaign could help drive growth into 2026.
INDV Stock: What Sublocade Growth Signals for 2026
Sublocade is powering Indivior's growth with record patient starts, rising volumes and a stable market share, setting up key demand tests for 2026.
Price Targets
Indivior price target lowered to $43 from $46 at Barclays
$43.00
(was $36.50)
Glen Santangelo
·
Barclays
Indivior price target raised to $53 from $50 at Craig-Hallum
$53.00
(was $36.94)
Chase Knickerbocker
·
Craig-Hallum
Indivior initiated with an Overweight at Barclays
$46.00
(was $37.93)
Barclays
Indivior price target raised to $50 from $40 at Northland
$50.00
(was $33.05)
Northland Securities
Indivior price target raised to $48 from $35 at H.C. Wainwright
$48.00
(was $35.44)
H.C. Wainwright
Indivior price target raised to $36 from $28 at Morgan Stanley
$36.00
(was $34.00)
Morgan Stanley
Indivior price target raised to $41 from $34 at Craig-Hallum
$41.00
(was $29.27)
Craig-Hallum
Indivior price target raised to $40 from $30 at Northland
$40.00
(was $29.67)
Northland Securities
Indivior price target raised to $35 from $28 at H.C. Wainwright
$35.00
(was $29.14)
Brandon Folkes
·
H.C. Wainwright
Indivior price target raised to $34 from $27 at Craig-Hallum
$34.00
(was $24.51)
Chase Knickerbocker
·
Craig-Hallum
Indivior price target lowered to $13 from $16 at Piper Sandler
$13.00
(was $9.89)
Piper Sandler
Piper Sandler Reiterates Overweight Rating on Indivior (INDV)
$15.00
(was $7.61)
David Amsellem
·
Piper Sandler
Indivior (INDV) PT Lowered to $20 at Craig-Hallum
$20.00
(was $9.16)
Chase Knickerbocker
·
Craig-Hallum
Piper Sandler Reiterates Overweight Rating on Indivior (INDV)
$22.00
(was $9.62)
David Amsellem
·
Piper Sandler
Indivior price target lowered to $24 from $37 at Craig-Hallum
$24.00
(was $10.19)
Chase Knickerbocker
·
Craig-Hallum
Craig-Hallum Starts Indivior (INDV) at Buy, 'overlooked and undervalued'
$37.00
(was $21.43)
Chase Knickerbocker
·
Craig-Hallum